ROXATIDINE ACETATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H28N2O4
Molecular Weight	348.4366
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1

InChI

InChIKey=SMTZFNFIKUPEJC-UHFFFAOYSA-N

InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23)

HIDE SMILES / InChI

Molecular Formula	C19H28N2O4
Molecular Weight	348.4366
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2861823
Curator's Comment: Description was created based on several sources, including http://www.drugsupdate.com/generic/view/456/Roxatidine | https://www.ncbi.nlm.nih.gov/pubmed/1717223 | https://www.ncbi.nlm.nih.gov/pubmed/20718616

Roxatidine is an histamine H2-receptor antagonist. Roxatidine is a potent and selective inhibitor of basal and stimulated gastric acid secretion through competitive blockade of H2-receptors. Total pepsin secretion is reduced in a dose-dependent manner. There is an independent mucosal protection action. Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome also it can be used as a premedication before anaesthesia. Roxatidine possessed a robust estrogenic activity.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H2 receptor 46 Target ID: CHEMBL1941 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2861823 \| https://www.ncbi.nlm.nih.gov/pubmed/1717223	Antagonist 2778
Estrogen receptor 75 Target ID: CHEMBL2093866 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20718616	Agonist 2678

Conditions

Condition	Modality	Highest Phase	Product
Peptic ulcer 72 Sources: http://www.drugsupdate.com/generic/view/456/Roxatidine	Primary	Approved 8429	ROXATIDINE Approved Use Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Gastroesophageal reflux disease 59 Sources: http://www.drugsupdate.com/generic/view/456/Roxatidine	Primary	Approved 8429	ROXATIDINE Approved Use Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Gastritis 45 Sources: http://www.drugsupdate.com/generic/view/456/Roxatidine	Primary	Approved 8429	ROXATIDINE Approved Use Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Upper gastrointestinal haemorrhage 4 Sources: http://www.drugsupdate.com/generic/view/456/Roxatidine	Primary	Approved 8429	ROXATIDINE Approved Use Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome
Zollinger-Ellison syndrome 17 Sources: http://www.drugsupdate.com/generic/view/456/Roxatidine	Primary	Approved 8429	ROXATIDINE Approved Use Roxatidine is indicated for the treatment of peptic ulcer, gastro-oesophageal reflux disease, gastritis, upper gastrointestinal haemorrhage and Zollinger-Ellison syndrome

PubMed

Title	Date	PubMed
Histamine H2-receptor antagonistic action of N-(3-[3-(1-piperidinylmethyl)phenoxy]propyl)acetoxyacetamide hydrochloride (TZU-0460).	1985	2861823
Penetration of roxatidine into the cerebrospinal fluid.	1988	2906459
Roxatidine, an H(2) receptor blocker, is an estrogenic compound--experimental evidence.	2010 Aug	20718616
Roxatidine attenuates mast cell-mediated allergic inflammation via inhibition of NF-κB and p38 MAPK activation.	2017 Jan 31	28139747

Patents

Sample Use Guides

In Vivo Use Guide

Peptic ulcer: 150 mg at bedtime or 75 mg bid daily for 4-6 weeks. Maintenance: 75 mg at bedtime. Gastro-oesophageal reflux disease: 75 mg bid or 150 mg at bedtime for 6-8 weeks. Gastritis: 75 mg once daily in the evening. Zollinger-Ellison syndrome: 75 mg bid. Premedication before anaesthesia: 75 mg in the evening on the day before surgery and repeated 2 hours before induction of anaesthesia. Alternatively, 150 mg once on the night before surgery. Intravenous Upper gastrointestinal haemorrhage: 75 mg bid via slow injection or infusion.

Route of Administration: Other

In Vitro Use Guide

6.25-25 uM Roxatidine suppressed the PMACI-induced production of pro-inflammatory cytokines in HMC-1

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:01:01 GMT 2023` Edited by `admin` on `Fri Dec 15 19:01:01 GMT 2023`
Record UNII	ZUP3LSD0DO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ROXATIDINE ACETATE

Common Name

English

ACETAMIDE, 2-(ACETYLOXY)-N-(3-(3-(1-PIPERIDINYLMETHYL)PHENOXY)PROPYL-

Common Name

English

Roxatidine acetate [WHO-DD]

Common Name

English

ROXATIDINE ACETATE [VANDF]

Common Name

English

PIFATIDINE

Common Name

English

ROXATIDINE ACETATE [MI]

Common Name

English

Code System Code Type Description

RXCUI

35803